TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

Company Overview

TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents. TriSalus collaborates with academic medical centers and cancer research institutions across the United States to advance its candidates through regulatory and clinical milestones. By integrating novel delivery technologies with proven oncology drugs, TriSalus seeks to optimize therapeutic outcomes in both recurrent and metastatic disease settings.

Headquartered in Houston, Texas, TriSalus operates research and development facilities in strategic North American life-science hubs. Its leadership team brings together seasoned professionals with backgrounds in pharmaceutical development, medical devices, and oncology therapeutics. As the company progresses through clinical validation, it plans to expand its technology platform into additional solid tumor indications, aiming to provide safer, more effective treatment options for cancer patients worldwide.

Key Stats

• Today's Range: $4.43 to $4.70
• 50-Day Range: $3.57 to $5.22
• 52-Week Range: $3.42 to $5.88
• Volume: 95,649 shs
• Average Volume: 122,175 shs
• Market Capitalization: $230.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.90
• Consensus Rating: Buy

TriSalus Life Sciences Stock Analysis - MarketRank™

TriSalus Life Sciences scored higher than 43% of companies evaluated by MarketBeat, and ranked 653rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

TriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

TriSalus Life Sciences has a consensus price target of $10.90, representing about 135.9% upside from its current price of $4.62.

Amount of Analyst Coverage

TriSalus Life Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TriSalus Life Sciences are expected to grow in the coming year, from ($1.55) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TriSalus Life Sciences is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TriSalus Life Sciences is -3.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.19% of the float of TriSalus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

TriSalus Life Sciences has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in TriSalus Life Sciences has recently increased by 12.75%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TriSalus Life Sciences does not currently pay a dividend.

Dividend Growth

TriSalus Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.19% of the float of TriSalus Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

TriSalus Life Sciences has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in TriSalus Life Sciences has recently increased by 12.75%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

TriSalus Life Sciences has a news sentiment score of -0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

MarketBeat Follows

3 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TriSalus Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.50% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.58% of the stock of TriSalus Life Sciences is held by institutions.

TLSI Stock Analysis - Frequently Asked Questions

How have TLSI shares performed this year?

TriSalus Life Sciences' stock was trading at $5.01 on January 1st, 2025. Since then, TLSI shares have decreased by 7.8% and is now trading at $4.62.

How were TriSalus Life Sciences' earnings last quarter?

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) issued its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.05. The business earned $11.21 million during the quarter, compared to the consensus estimate of $10.69 million.
Read the conference call transcript.

How do I buy shares of TriSalus Life Sciences?

Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TriSalus Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/06/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TLSI
• Previous Symbol: NASDAQ:TLSI
• CIK: 1826667
• Web: trisaluslifesci.com
• Phone: 888-321-5212
• Fax: N/A
• Employees: 106
• Year Founded: 2009

Price Target and Rating

• Average Price Target for TriSalus Life Sciences: $10.90
• High Price Target: $12.50
• Low Price Target: $10.00
• Potential Upside/Downside: +135.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$30.05 million
• Net Margins: -86.61%
• Pretax Margin: -86.61%
• Return on Equity: N/A
• Return on Assets: -116.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.08
• Quick Ratio: 3.68

Sales & Book Value

• Annual Sales: $35.99 million
• Price / Sales: 6.40
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.83) per share
• Price / Book: -5.57

Miscellaneous

• Outstanding Shares: 49,867,000
• Free Float: 36,154,000
• Market Cap: $230.39 million
• Optionable: Not Optionable
• Beta: 0.47